Mechanistically, PRMT5 has been revealed as an epigenetic executer of MYC, contributing to suppression of the transcription of downstream genes that support carcinogenesis in HCC, highlighting a direction for MYC-driven HCC via PRMT5 inhibition [22]. This evidence concerns the gene PRMT5 and hepatocellular carcinoma.